Prothena Q2 net loss $125.8M; prasinezumab to enter Phase 3 by end 2025

PROTHENA CORP PUBLIC LTD CO

2025-Q2 EPS reported -$3.45 revenue$7,248,000

Net loss $125.8M vs income $66.9M last year; includes $32.6M restructuring charge and $44.9M non-cash tax allowance.
Revenue $4.4M, down from $132.0M YoY; cash $372.3M with no debt; FY 2025 cash burn guidance $170-178M.
Partner Roche plans Phase 3 start for prasinezumab in early Parkinson's by end 2025; peak sales potential >$3B.
Initial Phase 1 data for PRX012 in Alzheimer's expected August 2025; up to $105M milestones possible in 2026.
Prothena to hold EGM by year-end to vote on share capital reduction for potential share redemption program.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.